Risks
4 risks
Risk Intelligence
High Working Capital Days
View Risks →Anlon Healthcare Ltd — Q3 FY26
Anlon Healthcare delivered a stellar Q3 FY26 with revenue surging to ₹35.78 Cr (up 281% YoY) and EBITDA margin of 35.06%, driven by higher API and intermediate volumes, operating leverage, and improved product mix.
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Anlon Healthcare delivered a stellar Q3 FY26 with revenue surging to ₹35.78 Cr (up 281% YoY) and EBITDA margin of 35.06%, driven by higher API and intermediate volumes, operating leverage, and improved product mix. PAT turned positive at ₹5.15 Cr vs a loss last year. Management guided for ~30% revenue CAGR over three years, with FY27 revenue of ₹370-380 Cr (conservative) supported by acquisitions of Epico Organics and Bizotic Life Sciences, which will add combined capacity of 1,400-1,600 MTPA. Key growth drivers include CDMO engagements (three molecules under validation), new API launches (7 in FY27), and expansion into peptides and formulations. Risks include high working capital days (currently ~290 days, target 150-160 by FY27) and execution risk in integrating acquisitions and greenfield capex of ₹100-120 Cr.
Risks4 trackedTranscriptfull text
Research workspace
Focused Modules
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Order Book (Existing Plant FY27)
₹180-190 Cr
+N/A
Existing plant order book for next year is completely booked with no spare reactor capacity.
Epico Order Book (FY27)
₹125-130 Cr
+N/A
Confirmed order book for Epico Organics for next financial year.
Combined Installed Capacity
1,400-1,600 MTPA
+250% vs current 400 MTPA
Post-acquisition of Epico and Bizotic, capacity expands significantly from current 400 MTPA.
Working Capital Days
~290 days
Target 150-160 days by FY27
Current receivable days high; management targets reduction through improved payment terms.
Fast read
Guidance and risk preview
Management expects consolidated revenue of ₹370-380 Cr for FY27, driven by existing operations and acquisitions, with potential upside.
Receivable days are currently ~290 days, posing cash flow risk.
View Risks →